Seattle Genetics, Takeda Report Mixed Data on Cancer Drug

Jun 27, 2017

Reuters

Seattle Genetics Inc.'s lymphoma drug, co-developed with Takeda Pharmaceutical Co., met the main goal in a late stage study, but the data did not meet investor expectations on the advantages over standard of care, and company stocks took a hit.

According to a Reuters article, Adcetris did help blood cancer patients live longer without worsening their condition, but the difference in the patient survival rate was about 5 percent - 82.1 percent for the drug versus 77.2 percent in the control arm.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments